Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC
First anti-PD-1 therapy approved in Europe for previously untreated patients with metastatic NSCLC.
Merck (MSD) has received approval from the European Commission for Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumuors have high PD-L1 expression (tumour proportion score [TPS] of 50% or more) with no EGFR or ALK positive tumour mutations.
“The approval of Keytruda as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic NSCLC is treated,” said Dr Roy Baynes, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories. “We are committed to ensuring that patients in Europe – who are in need of new treatment options – are able to quickly gain access to Keytruda.” The approval is based on Phase III data, which demonstrated superior overall survival (OS) and progression-free survival (PFS) with Keytruda compared with chemotherapy, the current standard of care for advanced NSCLC. The approval allows marketing of Keytruda in all 28 EU member states plus Iceland, Lichtenstein and Norway, at the approved dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity. In August 2016, Keytruda (pembrolizumab) (2 mg/kg every 3 weeks) was approved in Europe for previously-treated patients with locally advanced or metastatic NSCLC whose tumours express PD-L1 (TPS of 1% or more) and who have received at least one prior chemotherapy regimen. “The data demonstrate that Keytruda provided meaningful improvements in survival versus the current standard of care in patients whose tumours express high levels of PD-L1,” said Dr Luis Paz-Ares, chair of the medical oncology department, Hospital Universitario Doce de Octubre, Madrid, Spain. “These findings supporting the approval also provide further rationale for biomarker testing to identify those patients more likely to benefit the most from treatment with Keytruda.”
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance